

## SIERRA LEONE

### Support for Yellow Fever Vaccine

This Decision Letter sets out the Programme Terms of a Programme

<b>1. Country:</b>	Sierra Leone						
<b>2. Vaccine grant number:</b>	0715-SLE-06B-X, 16-SLE-06b-X, 17-SLE-06b-X, 1821-SLE-06b-X						
<b>3. Date of Decision Letter:</b>	30-Sep-2019						
<b>4. Date of the Partnership Framework Agreement:</b>	19 August 2013						
<b>5. Programme title:</b>	New Vaccine Support (NVS), Yellow Fever, Routine						
<b>6. Vaccine type:</b>	Yellow Fever						
<b>7. Requested product presentation and formulation of vaccine:</b>	Yellow Fever, 10 doses per vial, LYOPHILISED						
<b>8. Programme Duration:<sup>1</sup></b>	2003-2021						
<b>9. Programme Budget (indicative):<sup>2</sup></b>	(subject to the terms of the Partnership Framework Agreement, if applicable)						
	<b>2003-2019</b>	<b>2020</b>	<b>2021</b>	<b>2022</b>	<b>2023</b>	<b>2024</b>	<b>Total<sup>2</sup></b>
Programme Budget (US\$)	3,402,379	217,000	308,000	-	-	-	3,927,379
<b>10. Vaccine introduction grant</b>	Not applicable						
<b>11. Product switch grant</b>	Not applicable						
<b>12. Indicative Annual Amounts:<sup>3</sup></b>	(subject to the terms of the Partnership Framework Agreement, if applicable)						
<b>Type of supplies to be purchased with Gavi funds</b>	<b>2003-2019</b>	<b>2020</b>					<b>2021</b>
Number of vaccine doses			175,700				-
Annual Amounts (US\$)	3,402,379	217,000					-
<b>13. Procurement agency:</b>	UNICEF. The Country shall release its co-financing payments each year to UNICEF.						
<b>14. Self-procurement:</b>	Not applicable						

<sup>1</sup> This is the entire duration of the programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the programme.

<sup>3</sup> This is the amount that Gavi has approved.

**15. Co-financing obligations:**

According to the co-financing policy, the Country falls within the group: Initial self-financing

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2020	2021	2022	2023	2024
Number of vaccine doses	43,600	48,400	-	-	-
Number of AD syringes	-	-	-	-	-
Number of re-constitution syringes	-	-	-	-	-
Number of safety boxes	-	-	-	-	-
Value of vaccine doses (US\$)	51,332	57,002	-	-	-
Total co-financing payments (US\$) (including freight)	54,000	60,000	-	-	-

**16. Operational support for campaigns:**

Not applicable

**17. Additional Reporting Requirements:**

	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> <li>Vaccine stock levels including buffer stock</li> <li>Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received</li> </ul>	31 March 2020 15 May 2020
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat

<b>18. Financial clarifications:</b>	Not applicable
--------------------------------------	----------------

<b>19. Other conditions:</b>
------------------------------

Not applicable

Signed by,  
**On behalf of Gavi**



Thabani Maphosa,  
Managing Director, Country Programmes  
30-Sep-2019